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Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communica-
tion regarding the risks of atypical fractures of the femur, with bisphosphonates drugs. This study eval-
uated the impact of the bisphosphonates FDA safety communication on the utilization of osteoporosis
medications in Medicaid programs.
Methods: Osteoporosis drugs utilization data from the July 2006 to June 2014 were extracted from the
national Summary Files from the Medicaid State Drug Utilization Data maintained by the Centers for
Medicare & Medicaid Services (CMS). We performed an interrupted time series analyses to evaluate
trends in utilization of osteoporosis drugs before and after the 2010 FDA safety commination.
Results: Time-series analyses of osteoporosis drug utilization in Medicaid program revealed a significant
downward trend associated with the 2010 FDA bisphosphonates safety communication. Before the FDA
safety communication was issued, the utilization rate was slightly decreased between 2006 and 2010. In
the year following the FDA safety communication the bisphosphonate DDDs per 1000 beneficiaries of fell
22% yearly until the end of study period.
Conclusions: The 2010 FDA bisphosphonates safety communication appeared to have influenced
Osteoporosis utilization in Medicaid recipients. The 2010 FDA bisphosphonates safety communication
was associated with a significant reduction in the utilization of bisphosphonates in the Medicaid
program.
 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bisphosphonates are currently considered the first-line therapy
for the prevention and treatment of osteoporosis. In the United
States (US), 14.7 million prescriptions of oral bisphosphonates
were dispensed in 2012 (Wysowski and Greene, 2013).
Alendronate was the first bisphosphonate to obtain FDA approval
for the treatment and prevention of osteoporosis, followed by the
approval of several bisphosphonates with different efficacies and
dosing regimens (U.S. Food and Drug Administration, 2014a,b).
Several studies indicated the association between the long-term
use of bisphosphonates and the risk of atypical fracture of the femur
(Lenart et al., 2008; Shane et al., 2010; Abrahamsen et al., 2009). The
FDA reviewed these data and issued a Drug Safety Communication
(DSC) in 2010 regarding the risk of atypical femur fractures associ-
atedwith the long-term used of bisphosphonates. The FDA required
drug manufacturers to include a limitation of use statement, ‘‘The
optimal duration of use has not been determined. For patients at
low-risk for fracture, consider drug discontinuation after 3–5 years
of use,” on the label of all bisphosphonates approved for the treat-
ment of osteoporosis (U.S. Food andDrug Administration, 2014c). In
addition, a medication guide should be given to the patient with
each bisphosphonate prescription describing the risk and symp-
toms of these fractures (U.S. Food and Drug Administration,
2014c). The labeling changes and medication guide affected several
brands of bisphosphonates approved for osteoporosis and their
generic products (e.g., alendronate, alendronate and cholecalciferol,
risedronate, risedronate delayed release, ibandronate, zoledronic
acid) (U.S. Food and Drug Administration, 2014c).
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Despite the high prevalence and economic burden of osteoporo-
sis, the literature on the utilization and spending on osteoporosis
drugs is scarce (Lee et al., 2006; Udell et al., 2006). Furthermore,
no empirical studies have been conducted assessing trends in the
utilization and spending on osteoporosis drugs and the changes
in the patterns of bisphosphonate utilization in the Medicaid pro-
gram following the DSC are unknown. In an attempt to understand
how the FDA safety recommendation actions affected prescribing
practices, we investigated the utilization of bisphosphonates
before and after FDA regulatory actions in the Medicaid program
from July 2006 through June 2014.
2. Material and methods
2.1. Data sources
The primary data source is the National Summary Files from the
Medicaid State Drug Utilization Data maintained by the Centers for
Medicare and Medicaid Services (CMS). The data are fee-for-service
pharmacy claim records for outpatient drugs dispensed. This data
set is available for 49 states (except Arizona) and the District of
Colombia; it includes only outpatient pharmacy prescriptions
reimbursed by Medicaid in the period July 2006 through June
2014 (Centers for Medicare and Medicaid Service, 2014).
Each data record of this dataset includes: drug name, national
drug code (NDC), units reimbursed, number of prescriptions, and
total pharmacy reimbursement amount including drug cost and
dispensing fees. An updated list of osteoporosis drugs marketed
in the US was obtained from the U.S. Food and Drug Administration
(FDA) online databases. All osteoporosis drugs were identified by
their national drug codes (NDCs) using the FDA NDC directory (U.
S. Food and Drug Administration, 2014d). Information on missing
NDCs in the FDA NDC directory was compiled from Physicians’
Desk Reference (PDR).
The FDA regulatory data and the Medicaid state drug utilization
data for each osteoporosis drug were merged to create a unique
dataset that contained FDA regulatory data and Medicaid utiliza-
tion using the NDC and drug name.
2.2. Data analysis
Drug utilization was measured by the total defined daily doses
(DDDs). All drug units (e.g., tablets, nasal spray, injections) were
converted to DDDs using the World Health Organization Anatom-
ical Therapeutic Chemical/Defined Daily Dose (WHO ATC/DDD)
index (World Health Organization, 2013). When the DDD was
not available, the daily dose was calculated using the FDA labeling
information for drugs which is available on the FDA website. This
method allows for a comparison of the utilization and spending
of different osteoporosis drug classes using a standardized unit.
We conducted an interrupted time series analysis (ITS) to assess
the association of the 2010 FDA DSC on the utilization of bisphos-
phonates in the Medicaid program (Wagner et al., 2002; Ramsay
et al., 2003; Biglan et al., 2000). Interrupted time design is one of
the strongest quasi-experimental designs to assess the longitudinal
effects of an intervention (Ramsay et al., 2003; Biglan et al., 2000).
Autoregressive integrated moving average (ARIMA) techniques
are well established in the literature to perform a time series anal-
ysis (Veney and James, 1974; Pamer et al., 2010; Dorsey et al.,
2010; Niyomnaitham et al., 2014; Cohen et al., 2010). In contrast
with other techniques like a simple pre- and post-intervention
means test which results in overestimation or underestimation of
effect, ARIMA modeling takes into account secular trends and it
only requires data of the variables of interest for the analysis. Addi-
tionally ARIMA is more flexible than other techniques in fitting the
data (Cohen et al., 2010; Shumway and Stoffer, 2010; Matowe
et al., 2003).
Osteoporosis drug utilization and pharmacy reimbursement
were calculated per 1000 Medicaid beneficiaries to account for
changes over time in the number of Medicaid beneficiaries. The
time series ARIMA model also controlled for the demographic
changes in the Medicaid population adjusting for the proportion
of women 65 years and over.
A stepwise approach was used to select the best fit model by
adding different parameters to the model such as availability of
competitors’ drugs, introduction of new drugs and generic entry.
Akaike Information Criteria (AIC) were used to select the best fit-
ting model. Statistical significance was set at 0.05 (two-sided).
All statistical analyses were performed using SAS software, version
9.4 for Windows (SAS Institute, Inc., Cary, NC, USA).
3. Results
Five drug classes were used in this study (Table 1). Hormonal
replacement therapies (HRTs) are indicated for treatment of multi-
ple diseases and were excluded from analysis because it was not
possible to differentiate what percentage of the utilization of HRTs
was used for each disease. The following HRTs were excluded from
analysis: estropipate (approved in 1986), conjugated estrogens
(1986), estradiol (1994), conjugated estrogens and medroxypro-
gesterone acetate (1995), estradiol and norethindrone acetate
(1998), ethinyl estradiol and norethindrone acetate (1999), estra-
diol and norgestimate (1999), estradiol and levonorgestrel
(2006), and bazedoxifene acetate and conjugated estrogens (2013).
During the study period, bisphosphonates was the therapeutic
subclass with the highest percentage of utilization (Table 2) and
also represented the highest market share among other osteoporo-
sis drugs (Fig. 1). The utilization of bisphosphonates increased
since the approval of alendronate. In the beginning of the study
period third quarter of 2006, the utilization of bisphosphonates
was 252.6 DDDs per 1000 beneficiaries. The trends in bisphospho-
nate utilization in the Medicaid program decreased by 3% annually
and reached 218.7 DDDs per 1000 beneficiaries at the end of 2010.
The first-order autoregressive model was selected as the best fit
model using AIC. Finding from the ARIMA model indicated a signif-
icant decrease in the utilization of bisphosphonates following the
issue of the DSC in October 2010 (p < .001) (Table 3). The DSC
resulted in a decrease of 31 DDDs per 1000 beneficiaries per quar-
ter in Medicaid bisphosphonate utilization (95% CI: 14.65 to
52.5, p = .001).
No such trends were observed for other osteoporosis drugs such
as SERMs, teriparatide and calcitonins. The utilization of SERMs
decreased from 19.62 DDDs per 1000 beneficiaries in the third
quarters of 2006 to 15.77 DDDs per 1000 beneficiaries followed
Table 1
List of osteoporosis drugs included in the study.
Chemical subgroup Active ingredient(s) FDA approval
year







Calcitonins Calcitonin salmon 1995
Calcitonin salmon recombinant 2005
Parathyroid
hormones
Teriparatide recombinant human 2002
RANKL inhibitors Denosumab 2010
SERM Raloxifene hydrochloride 1997
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by a decreased in the fourth quarter of 2011 however the trends
were not statistically significant (p = .33).
For SERM, although we can see a decline after the 2010 FDA
DSC, there is no statistically significant effect on utilization of
SERM after fitting this into ARIMA model (Table 3). Calcitonins
had a steady decrease in its utilization at a rate of 5.2% per quarter
from 4.4 DDDs per 1000 beneficiaries to 0.71 DDDs per 1000 ben-
eficiaries at the end of study period, and the utilization of teri-
paratide was shown to decrease by 0.0846 each quarter until the
second quarter of 2014. The reduction of calcitonins and teri-
paratide were not associated with the 2010 FDA DSC (p = .655, p
= .293) (Fig. 2).
Denosumab entered the market as a first-line therapy for
patients with severe osteoporosis in June 1, 2010. The utilization
of denosumab was 0.04 DDDs per 1000 and increased at a rate of
27% and reached 20.2039 DDDs per 1000 by June 2014. However,
Table 3
Impact of the FDA safety communication on bisphosphonate utilization.
Model Intervention Adjusted for Coefficienta SE t P valueb
ARIMA* (1, 0, 0) 2010_FDA Women, aged
Bisphosphonates 30.948 8.184 3.781 .001
Calcitonins 0.053 0.117 0.452 .655
SERM 1.625 1.516 1.072 .332
Teriparatide 0.149 0.132 1.129 .293
* The model was adjusted for percentage of elderly and women in Medicaid program.
a Coefficient = utilization changed after the intervention take place.
b Statistical significant set at p value < .05.
Table 2
Utilization of osteoporosis drugs in the medicaid fee-for-service program (Q3 2006–Q2 2014).
Year DDDs per 1000 beneficiaries Market share as percentage of total DDD
Total BP Teriparatide Calcitonin SERM Denosumab BP (%) Teriparatide (%) Calcitonin (%) SERM (%) Denosumab (%)
Utilization
2006 559.1 506.1 5.89 8.42 38.7 – 90.50 1.10 1.50 6.90 –
2007 1109.18 1014.35 11.19 15.55 68.09 – 91.50 1.00 1.40 6.10 –
2008 1027.35 934.47 9.74 16.16 66.98 – 91.00 0.90 1.60 6.50 –
2009 1005.16 921.89 7.36 13.39 62.51 – 91.70 0.70 1.30 6.20 –
2010 945.44 865.86 7.45 9.9 61.92 0.31 91.60 0.80 1.00 6.50 0.00
2011 567.72 502.72 6.18 7.58 46.86 4.38 88.60 1.10 1.30 8.30 0.80
2012 278.41 226.23 3.39 5.8 13 30 81.30 1.20 2.10 4.70 10.80
2013 241.93 167.34 2.72 4.07 9.65 58.16 69.20 1.10 1.70 4.00 24.00
2014 112.92 73.39 1.17 1.42 3.69 33.25 65.00 1.00 1.30 3.30 29.40
Fig. 1. Market share of osteoporosis drug defined daily dose in the medicaid fee-for-service program (Q3 2006-Q2 2014).
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our model indicated that the increase in the utilization of deno-
sumab during the post FDA warning period was not statistically
significant (p value = .751). This means that the DSC did not affect
the utilization of this drug. Among bisphosphonate drugs, alen-
dronate was associated with the highest utilization by Medicaid
recipients. All branded and generic bisphosphonates drugs were
affected by the 2010 DSC (Fig. 3).
4. Discussion
During the last twenty years, the FDA approved several osteo-
porosis drugs from five different therapeutic subclasses. In January
1995, only one osteoporosis drug (other than HRTs and calcitonin)
was available in the US market. By the end of 2014, the FDA had
approved 9 single active ingredients and 2 fixed dose combination
drugs.
Study findings reveal a significant change in the pattern of
osteoporosis drugs. During the period between 2006 and before
the FDA issued the DSC in 2010, we observed a decrease in the uti-
lization of bisphosphonates and other osteoporosis drugs. Previous
studies on the use of bisphosphonates observed a significantly
decrease in the use of bisphosphonates in the US in patients under
45 years (Xie et al., 2015), and a decrease in overall osteoporosis
drugs post-fragility fracture (Balasubramanian et al., 2014).
The safety of bisphosphonate drugs has been addressed in sev-
eral studies which indicate an association between the long-term
use of bisphosphonates and the risk of an atrial fibrillation
(Cummings et al., 2007), severe musculoskeletal pain (Wysowski
and Chang, 2005; Bock et al., 2007), typical fracture of the femur
(Lenart et al., 2008; Shane et al., 2010; Abrahamsen et al., 2009)
and esophageal cancer (Cardwell et al., 2010). The FDA has investi-
gated these risks and issued several DSCs on the use of bisphospho-
nates in the treatment and prevention of osteoporosis (U.S. Food
and Drug Administration, 2008a,b; Bunch et al., 2009). The FDA
did not conclude that taking bisphosphonates increases the risk
of atrial fibrillation or esophageal cancer. However, the FDA issued
a warning regarding atypical fractures with the long-term used of
bisphosphonates. As a result, the FDA required substantial changes
in bisphosphonate labels.
In the case of alendronate, the FDA approved a total of 33 sup-
plements including 2 new or modified indications and 22 labeling
revisions in the period 2000–April 2014. Alendronate labeling
safety revisions were related to the following: gastrointestinal
warnings (2002); scleritis and symptomatic hypocalcemia post-
marketing adverse reports, and severe skin adverse post-
marketing adverse reports (2003); theoretical risk of fetal harm
(2004); episcleritis post-marketing adverse reports and
osteonecrosis of the jaw precautions (2005); asthenia, dizziness,
joint swelling, peripheral edema, and vertigo post-marketing
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alopecia post-marketing adverse reports (2008), low-energy
femoral shaft and subtrochanteric fractures post-marketing
adverse reports, osteonecrosis of the jaw precautions and post-
marketing adverse reports, and revision of the warnings related
to gastrointestinal adverse events associated with the use of bis-
phosphonates (2010); and osteonecrosis of the jaw warnings and
precautions, and asthma exacerbations post-marketing adverse
reports (2013). Additionally, the FDA required a risk evaluation
and mitigation strategy (REMS) with information pertains to the
risk of atypical subtrochanteric and diaphyseal femoral fractures
with the bisphosphonate drug class in 2010. The FDA decided in
2011 that the REMS for alendronate were no longer required.
In spite of the number of safety label changes, the utilization of
alendronate did not significantly change until the 2010 warnings,
precautions and REMS. Given that safety actions including warn-
ings, precautions and post-marketing adverse reports released by
the FDA before 2010 did not significantly change the use of bispho-
sphonates, we hypothesized that the changes in utilization
observed after 2010 were related to the implementation of REMS
for bisphosphonates that required communications of the risks to
patients before starting the therapy.
The 2010 DSC was associated with a significant change in the
pattern of utilization of osteoporosis drugs. Although there was
an overall decline in the utilization of osteoporosis drugs, our find-
ings indicated that the 2010 DSC only significantly affected the uti-
lization of bisphosphonates. Our regression model points to a
delayed effect of the DSC on the utilization of SERMs, as a sharp
decline in the utilization of SERMs in Medicaid began in the fourth
quarter of 2011, a year after the DSC was released by the FDA. This
reduction in SERMs may be due to factors not assessed in this
study.
We also noted that the decrease in the utilization of bisphos-
phonates was associated with an increase in denosumab use in
the same period, but our results indicated that this increase was
not related to the DSC. This increase may be related to the fact that
denosumab is indicated for patients with severe osteoporosis.
The Medicaid population increased during the study period from
33million in 1995 to 65million in 2014. The demographic distribu-
tion of the Medicaid population also changed during this study per-
iod. While women represented around 59% of the total Medicaid
population during the entire period of analysis, the percentage of
the population aged 65 and older, that are more likely to use osteo-
porosis drugs, decreased from 12% in 1995 to 8% in 2014.
This study has several limitations. Information about the char-
acteristics of the Medicaid patient population using osteoporosis
drugs is not available for analysis of the impact of FDA DSC on
patient care. Also, the utilization of osteoporosis drugs was esti-
mated using DDDs. The DDDs do not represent the actual or FDA
approved recommended daily dosages for osteoporosis drugs.
Finally, these results relate to the Medicaid program and may not
be generalizable to a broader population.
5. Conclusions
Time series analyses of osteoporosis drug utilization in the
Medicaid program showed a significant reduction in the use of bis-
phosphonates following the 2010 bisphosphonate FDA drug safety
communication. This drug safety communication appears to have
had a similar effect on other classes of osteoporosis drugs with
the exception of denosumab. However, without clinical data, the
appropriateness of the effect on this regulatory action is uncertain.
Further research may evaluate the effect of the decline in utiliza-
tion of osteoporosis drugs on fractures.
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